Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil

BACKGROUND Hepatitis C virus (HCV) treatment has undergone major changes in recent years. Previous interferon-based therapies have been replaced by oral direct-acting antivirals (DAA) regimens, with high sustained virologic response (SVR) rates, and a lower incidence of adverse events (AEs). AIM To evaluate the efficacy and safety of DAAs for HCV treatment in subjects from two tertiary university centers in Brazil. METHODS This is a multicenter retrospective cohort study of 532 patients with chronic hepatitis C (CHC), undergoing treatment with interferon-free regimens from November 2015 to November 2019. The therapeutic regimen was defined by the current Brazilian guidelines for HCV management at the time of treatment. Demographic, anthropometric, clinical, and laboratory variables were evaluated. SVRs were assessed at 12 to 24 wk after therapy by intention-to-treat (ITT), and modified ITT (m-ITT) analysis. AEs and serious adverse events (SAEs) were registered. In the statistical analysis, a P value of < 0.05 was considered significant. RESULTS The mean age was 56.88 years, with 415 (78.5%) being HCV genotype 1, followed by genotype 3 (20.1%). Moreover, 306 (57.5%) subjects had cirrhosis, and a third of them had decompensated cirrhosis. Sofosbuvir (SOF) plus daclatasvir ribavirin was the most frequently used treatment (66.9%), followed by SOF plus simeprevir (21.2%). The overall ITT SVR was 92.6% (493/532), while the m-ITT SVR was 96.8% (493/509). Variables associated with treatment failure via ITT evaluation were hepatic encephalopathy (OR: 4.320; 95%CI: 1.920-9.721, P = 0.0004), presence of esophageal varices (OR: 2.381; 95%CI: 1.137-4.988, P = 0.0215), previous portal hypertensive bleeding (OR: 2.756; 95%CI: 1.173-6.471, P = 0.02), higher model for end-stage liver disease scores (OR: 1.143, 95%CI: 1.060-1.233, P = 0.0005), lower serum albumin levels (OR: 0.528, 95%CI: 0.322-0.867, P = 0.0115), higher serum creatinine (OR: 1.117, 95%CI: 1.056-1.312, P = 0.0033), and international normalized ratio (INR) levels (OR: 5.542, 95%CI: 2.023-15.182, P = 0.0009). AEs were reported in 41.1% (211/514) of patients, and SAEs in 3.7%. The female gender, higher body mass index, esophageal varices, higher INR values, and longer treatment duration were independently associated with AE occurrence. CONCLUSION Treatment with oral DAAs attains a high SVR rate, with fewer SAEs in a real-life cohort of subjects with CHC, from two tertiary university centers in Brazil.

Palavras-chave

Chronic hepatitis C, Antiviral agents, Hepatitis C virus, Sustained virologic response, Liver cirrhosis, Safety

URI

https://observatorio.fm.usp.br/handle/OPI/48400

Referências

Afdhal N, 2014, NEW ENGL J MED, V370, P1889, DOI 10.1056/NEJMoa1402454
Ampuero J, 2014, ALIMENT PHARM THER, V39, P686, DOI 10.1111/apt.12646
[Anonymous], 2017, WHO GLOBAL HEPATITIS
Benzaken AS, 2019, BRAZ J INFECT DIS, V23, P182, DOI 10.1016/j.bjid.2019.04.010
Blach S., 2017, LANCET GASTROENTEROL, V2, P161
Burki T, 2020, LANCET, V396, P1058, DOI 10.1016/S0140-6736(20)32111-5
Daniel KE, 2020, J VIRAL HEPATITIS, V27, P195, DOI 10.1111/jvh.13218
Lobato CMD, 2019, ANN HEPATOL, V18, P849, DOI 10.1016/j.aohep.2019.08.001
Falade-Nwulia O, 2017, ANN INTERN MED, V166, P637, DOI [10.7326/M16-2575, 10.7326/m16-2575]
FEINSTONE SM, 1975, NEW ENGL J MED, V292, P767, DOI 10.1056/NEJM197504102921502
Garioud A, 2019, EUR J GASTROEN HEPAT, V31, P1270, DOI 10.1097/MEG.0000000000001450
Gheorghe LS, 2020, J GASTROINTEST LIVER, V29, P385, DOI 10.15403/jgld-2448
Gondeau C, 2015, WORLD J GASTROENTERO, V21, P12101, DOI 10.3748/wjg.v21.i42.12101
Grando AV, 2017, REV INST MED TROP SP, V59, DOI [10.1590/S1678-9946201759067, 10.1590/s1678-9946201759067]
Holzmann I, 2018, BRAZ J INFECT DIS, V22, P317, DOI 10.1016/j.bjid.2018.06.004
Lawitz E, 2016, HEPATOLOGY, V64, P360, DOI 10.1002/hep.28422
Lawitz E, 2015, HEPATOLOGY, V61, P769, DOI 10.1002/hep.27567
Calleja JL, 2017, J HEPATOL, V66, P1138, DOI 10.1016/j.jhep.2017.01.028
Maan R, 2016, CLIN GASTROENTEROL H, V14, P1821, DOI 10.1016/j.cgh.2016.07.001
Machado MAD, 2019, J MANAG CARE SPEC PH, V25, P697, DOI 10.18553/jmcp.2019.25.6.697
Macken L, 2019, J MED VIROL, V91, P1979, DOI 10.1002/jmv.25552
Martinello M, 2020, GASTROENTEROL CLIN N, V49, P253, DOI 10.1016/j.gtc.2020.01.005
Medeiros T, 2017, INT J CLIN PHARM-NET, V39, P1304, DOI 10.1007/s11096-017-0552-1
Minist?rio da Sa?de (MS), 2019, SECR VIG SAUD DEP VI
Ministerio da Saude (BR), 2020, SECRETARIA VIGILANCI
Ministrio daSade, 2015, SECR VIG SAD DEP DST
Ministrio daSade.,, 2018, SECR VIG SAD DEP DST
Miotto N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199941
Miotto N, 2017, EUR J GASTROEN HEPAT, V29, P1149, DOI 10.1097/MEG.0000000000000944
Mucke MM, 2018, LIVER INT, V38, P14, DOI 10.1111/liv.13636
National InstitutesofHealthNationalCancerInstitute.,, 2009, CTCAE 4 03 COMM TERM
Nelson DR, 2015, HEPATOLOGY, V61, P1127, DOI 10.1002/hep.27726
Ohya K, 2020, HEPATOL RES, V50, P1234, DOI 10.1111/hepr.13555
Organization W.H., 2018, GUID CAR TREATM PERS
Pawlotsky JM, 2020, J HEPATOL, V73, P1170, DOI 10.1016/j.jhep.2020.08.018
Sarrazin C, 2021, J HEPATOL, V74, P1472, DOI 10.1016/j.jhep.2021.03.004
Sette H, 2017, ANN HEPATOL, V16, P727, DOI 10.5604/01.3001.0010.2717
Sulkowski MS, 2014, NEW ENGL J MED, V370, P211, DOI 10.1056/NEJMoa1306218
Tada T, 2017, J GASTROEN HEPATOL, V32, P687, DOI 10.1111/jgh.13589
van der Meer AJ, 2012, JAMA-J AM MED ASSOC, V308, P2584, DOI 10.1001/jama.2012.144878
World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053

Coleções

Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - ODS/03

Página do item completo